ホーム>>Lipids>> Leukotrienes>>Zileuton-d4

Zileuton-d4

カタログ番号GC48267

ジルートンの定量化のための内部標準物質

Products are for research use only. Not for human use. We do not sell to patients.

Zileuton-d4 化学構造

Cas No.: 1189878-76-9

サイズ 価格 在庫数 個数
500 μg
$170.00
在庫あり
1 mg
$321.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Zileuton-d4 is intended for use as an internal standard for the quantification of zileuton by GC- or LC-MS. Zileuton is a reversible 5-lipoxygenase (5-LO) inhibitor.1 It inhibits 5-LO activity in rat basophilic leukemia-1 (RBL-1) cell supernatant with an IC50 value of 0.5 µM. Zileuton inhibits leukotriene B4 production induced by the calcium ionophore A23187 in purified human peripheral blood polymorphonuclear leukocytes (PMNLs; IC50 = 0.6 µM). Zileuton (10 mg/kg, p.o.) prevents antigen challenge-induced increases in specific lung resistance in a sheep model of asthma at 4 to 8 hours post-challenge following administration 2 hours pre-challenge.2 Formulations containing zileuton have been used in the prophylaxis and chronic treatment of asthma.

1.Carter, G.W., Young, P.R., Albert, D.H., et al.5-Lipoxygenase inhibitory activity of zileutonJ. Pharmacol. Exp. Ther.256(3)929-937(1991) 2.Abraham, W.M., Ahmed, A., Cortes, A., et al.The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheepEur. J. Pharmacol.217(2-3)119-126(1992)

レビュー

Review for Zileuton-d4

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Zileuton-d4

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.